Revenue and profit declined due to lower volumes and competitive pressures, but EBITDA margins remained robust. Health segment showed strong sequential growth, new products were commercialized, and capacity expansions are underway. Market uncertainties and tariffs continue to pose risks.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.